Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD

Inclusion Criteria: * Subject is between 21 - 70 years of age. * Subject has a history of heartburn, regurgitation or both for \> 12 month prompting physician recommendation of continual daily use of PPI before study entry. * Baseline GERD HRQL heartburn score following 10-14 days off PPI which is ≥ 20 and at least 10 points higher than the on PPI score * Subject who are on standard medical therapy for 12 months or longer and experience discomfort or who are otherwise dissatisfied with GERD symptoms * Subjects with a GERD condition that in the opinion of the PI justifies a minimally invasive reversible procedure prior to attempting anatomical change such as Nissen fundoplication * Subject has an American Society of Anesthesiologists (ASA) Physical Status Classification I or II (or comparable local classification if any). * Subject has exhibited excessive lower esophageal acid exposure during 24-hour pHmetry of antisecretory therapy performed within 6 months of screening visit; pH \< 4 for \> 5% of total time. * Subject has a resting LES end expiratory pressure \> 5mm Hg and \< 15 mm Hg on a high resolution manometry within 6 months of enrollment. * Subject has esophagitis ≤ Grade C (LA classification) on upper endoscopy within 6 months of enrollment. * Subject has esophageal body contraction amplitude \> 30 mmHg for \> 50% of swallows and \> 50% peristaltic contractions on high resolution manometry. * Subject has signed the informed consent form and is able to adhere to study visit schedule. Exclusion Criteria: * Subject has any non-GERD esophageal motility disorders. * Subject has gastroparesis. * Subject has any significant multisystem diseases. * Subject has an autoimmune or a connective tissue disorder (e.g. scleroderma, dermatomyositis, Calcinosis-Raynaud's-Esophagus, Sclerodactyly Syndrome (CREST), Sjogren's Syndrome, Sharp's Syndrome), requiring therapy in the preceding 2 years. * Subject has Barrett's epithelium (\> M2; \> C1) or any grade of dysplasia. * Subject has a hiatal hernia larger than 3 cm. * Subject has a body mass index (BMI) greater than 35 kg/m2. * Subject has Type 1 diabetes mellitus * Subject has uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c \> 9.5 in the previous 6 months, or has T2DM for \> 10 years. * Subject has a history of suspected or confirmed esophageal or gastric cancer. * Subject has esophageal or gastric varices. * Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease. * Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD). * Subject requires chronic anticoagulant therapy. * Subject has dysphagia or esophageal peptic stricture, excluding Schatzki's ring. * Subject of child-bearing potential who is pregnant or intends to become pregnant during the trial period. * Subject is currently enrolled in other potentially confounding research. * History of any malignancy in the last 2 years. * History of previous esophageal or gastric surgery, including nissen fundoplication. * Subject has any condition that, at the discretion of the investigator or sponsor, would preclude participation in the trial.